KOA Biotech, a Pompeu Fabra University spin-off, raised €2M to develop biosensors for early infection detection in fish farms. Led by Swanlaab, Fund-F, and FABER, the...
CRISPR specialist Akribion Therapeutics, a 2024 spin-off from BRAIN Biotech, raised €8M in seed funding led by CARMA FUND and RV Invest. The funds will support...
Inventiva’s stock surged over 80% on news of phase III trial financing for lanifibranor, targeting NASH liver disease. The €94.1 million initial funding will support trials...
Some of the big companies in the biotech sector have already outlined their plans for the new phase. For now, the largest U.S. biotech companies have...
With the $57 million (€50 million), SpliceBio aims to bring this strategy to the clinical phase (human trials) in about 2 to 3 years. Its aim...